Journal Home > Volume 4 , Issue 1
Journal of Neurorestoratology 2016, 4(1): 45-50 https://doi.org/10.2147/JN.S98584
Case Report | Open Access | Issue | Published: 08 July 2016

Cell-based neurorestorative therapy for postpoliomyelitis syndrome: a case report

Show Author's Information Haitao Xi1,2,*( ),  Di Chen1,*
Center of Neurorestoratology, Beijing Hongtianji Neuroscience Academy,
Center of Neurorestoratology, Beijing Rehabilitation Hospital affiliated Capital Medical University, Beijing, People’s Republic of China

*These authors contributed equally to this work

Keywords:
cell transplantation, neuromuscular disease, postpoliomyelitis syndrome, cell-based neurorestorative therapy
Cite this article:
Xi H, Chen D. Cell-based neurorestorative therapy for postpoliomyelitis syndrome: a case report. Journal of Neurorestoratology, 2016, 4(1): 45-50. https://doi.org/10.2147/JN.S98584
Download citation
EndNote(RIS)
BibTeX

490

Views

19

Downloads

Citations

4

Crossref

4

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Postpoliomyelitis syndrome refers to the new neuromuscular symptoms that occur in patients, years after their acute poliomyelitis has stabilized. A 64-year-old Danish man presented with lower limb weakness and severe pain for 2 years and 5 months. He had a history of poliomyelitis affecting his limbs 59 years ago. Physical examination revealed atrophy of muscles of both lower limbs. Electromyography revealed that recruitment of maximal voluntary contraction of muscles was decreased in the affected muscles. He received cell-based neurorestorative therapy during admission, and then, his neurological function improved and remained stable during 4-year follow-up. This case report shows that cell therapy could be a treatment option for postpoliomyelitis syndrome.


menu
Abstract
Full text
Outline
About this article

Cell-based neurorestorative therapy for postpoliomyelitis syndrome: a case report

Show Author's information Haitao Xi1,2,*( ), Di Chen1,*
Center of Neurorestoratology, Beijing Hongtianji Neuroscience Academy,
Center of Neurorestoratology, Beijing Rehabilitation Hospital affiliated Capital Medical University, Beijing, People’s Republic of China

*These authors contributed equally to this work

Abstract

Postpoliomyelitis syndrome refers to the new neuromuscular symptoms that occur in patients, years after their acute poliomyelitis has stabilized. A 64-year-old Danish man presented with lower limb weakness and severe pain for 2 years and 5 months. He had a history of poliomyelitis affecting his limbs 59 years ago. Physical examination revealed atrophy of muscles of both lower limbs. Electromyography revealed that recruitment of maximal voluntary contraction of muscles was decreased in the affected muscles. He received cell-based neurorestorative therapy during admission, and then, his neurological function improved and remained stable during 4-year follow-up. This case report shows that cell therapy could be a treatment option for postpoliomyelitis syndrome.

Keywords: cell transplantation, neuromuscular disease, postpoliomyelitis syndrome, cell-based neurorestorative therapy

References(33)

1.
Willén C, Thorén-Jönsson, AL, Grimby G, Sunnerhagen, KS. Disability in a 4-year follow-up study of people with post-polio syndrome. J Rehabil Med. 2007;39(2):175-180.
DOI Google Scholar
2.
Corrêa JC, Rocco CC, de Andrade DV, Peres JA, Corrêa FI. Electromyographic and neuromuscular analysis in patients with post-polio syndrome. Electromyogr Clin Neurophysiol. 2008;48(8):329-333.
Google Scholar
3.
Trojan DA, Cashman NR. Post-poliomyelitis syndrome. Muscle Nerve. 2005;31(1):6-19.
DOI Google Scholar
4.
Gonzalez H, Sunnerhagen KS, Sjöberg I, Kaponides G, Olsson T, Borg K. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 2006;5(6):493-500.
DOI Google Scholar
5.
Oncu J, Durmaz B, Karapolat H. Short-term effects of aerobic exercise on functional capacity, fatigue, and quality of life in patients with post-polio syndrome. Clin Rehabil. 2009;23(2):155-163.
DOI Google Scholar
6.
Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62(5):571-579.
DOI Google Scholar
7.
Boyer FC, Tiffreau V, Rapin A, Laffont I, Percebois-Macadré L, Supper C, Novella JL, Yelnik AP. Post-polio syndrome: Pathophysiological hypotheses, diagnosis criteria, medication therapeutics. Ann Phys Rehabil Med. 2010;53(1):34-41.
DOI Google Scholar
8.
Chen L, Huang HY. [Neurorestoratology: new concept and bridge from bench to bedside]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23(3):366-370.
Google Scholar
9.
International Association of Neurorestoratology. Beijing declaration of international association of neurorestoratology (IANR). Cell Transplant. 2009;18(4):487.
DOI Google Scholar
10.
Liu K, Li Y, Wang H, et al. The immunohistochemical characterization of human fetal olfactory bulb and olfactory ensheathing cells in culture as a source for clinical CNS restoration. Anat Rec (Hoboken). 2010;293(3):359-369.
DOI Google Scholar
11.
Huang H. Neurorestoratology, a distinct discipline and a new era: a brief introduction to the first IANR section. Cell Transplant. 2010;19(2):129-131.
DOI Google Scholar
12.
Huang H, Chen L, Sanberg P. Cell therapy from bench to bedside translation in CNS neurorestoratology era. Cell Med. 2010;1(1):15-46.
DOI Google Scholar
13.
Sanberg PR, Eve DJ, Willing AE, et al. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant. 2011;20(1):85-94.
DOI Google Scholar
14.
Huang HY, Chen L, Xi H, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant. 2008;22(6):710-718.
DOI Google Scholar
15.
Huang HY, Xi HT, Chen L, Zhang F, Liu YC. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Clin Transplant. 2012;21(S1):S23-31.
DOI Google Scholar
16.
Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma. 2011;28(8):1611-1682.
DOI Google Scholar
17.
Chen L, Huang HY, Xi HT, et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial. Cell Transplant. 2010;19(2):185-191.
DOI Google Scholar
18.
Chen L, Chen D, Xi HT, et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplantat. 2012;21(Supp 1):S65-77.
DOI Google Scholar
19.
Bohbot A. Olfactory ensheathing glia transplantation combined with laserponcture® in human spinal cord injury: results measured by electromyography monitoring. Cell Transplant. 2010;19:179-184.
DOI Google Scholar
20.
People’s Republic of China, Ministry of Public Health, Science and Technology Bureau, 1991. Instruction for prepare and clinical application of the aborted human fetuses (91-006).
21.
Xi HT, Chen L, Huang HY, et al. Preliminary report of multiple cell therapy for patients with multiple system atrophy. Cell Transplant. 2013;22 (Suppl 1):S93-S99.
DOI Google Scholar
22.
Chen L, Xi HT, Huang H, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013;22 (Suppl 1):S83-S91.
DOI Google Scholar
23.
Ditunno JF Jr. American spinal injury standards for neurological and functional classification of spinal cord injury: past, present and future. 1992 Heiner Sell lecture of the American Spinal Injury Association. J Am Paraplegia Soc. 1994;17(1):7-11.
DOI Google Scholar
24.
International Association of Neurorestoratology. Clinical application of the principle of cell transplantation in neurorestoratology. Chinese J Reparat Reconstruct Surg. 2008;22(8):1021-1023. Available from: http://www.ianr.org.cn/images/SCI-FRS(Seeking%20Suggestions).pdf.
Google Scholar
25.
Okano H. Neural stem cells and strategies for the regeneration of the central nervous system. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(4):438-450.
DOI Google Scholar
26.
Orlacchio A, Bernardi G, Orlacchio A, Martino S. Stem cells: an overview of the current status of therapies for central and peripheral nervous system diseases. Curr Med Chem. 2010;17(7):595-608.
DOI Google Scholar
27.
Huang HY, Chen L, Xi HT, et al. [Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23(1):14-20.
Google Scholar
28.
Pastuszak Ż, Tomczykiewicz K, Stępień A. Post-polio syndrome – a case report. Pol Merkur Lekarski. 2015;39(229):37-39.
Google Scholar
29.
Wang F, Yasuhara T, Shingo T, et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1 alpha. BMC Neurosci. 2010;11(1):52.
DOI Google Scholar
30.
Blits B, Boer GJ, Verhaagen J. Pharmacological cell and gene therapy strategies to promote spinal cord regeneration. Cell Transplant. 2002;11(6):593-613.
DOI Google Scholar
31.
Ramon-Cueto A, Valverde F. Olfactory bulb ensheathing glia: a unique cell type with axonal growth-promoting properties. Glia. 1995;14(3):163-173.
DOI Google Scholar
32.
Meng J, Adkin CF, Arechavala-Gomeza V, Boldrin L, Muntoni F, Morgan JE. The contribution of human synovial stem cells to skeletal muscle regeneration. Neuromuscul Disord. 2010;20(1):6-15.
DOI Google Scholar
33.
Yohn DC, Miles GB, Rafuse VF, Brownstone RM. Transplanted mouse embryonic stem-cell-derived motoneurons form functional motor units and reduce muscle atrophy. J Neurosci. 2008;19;28(47):12409-12418.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Published: 08 July 2016
Issue date: December 2016

Copyright

© 2016 The Author(s).

Rights and permissions

© 2016 Xi and Chen. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Return